Skip to main content

Table 1 Patient demographics and disease characteristics

From: Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

Characteristic Lapatinib + vinorelbine (N=44)*
Age, years  
 Median (range) 56.0 (29–82)
Race, n (%)  
 Caucasian/White 32 (73)
 African American/African heritage 12 (27)
ECOG status at baseline, n (%)  
 0 25 (57)
 1 19 (43)
HER2 status, n (%)  
 FISH+ (with or without IHC+) 27 (61)
 IHC 3+ (only) 29 (66)
ER/PgR status, n (%)  
 ER+ and/or PgR+ 23 (52)
 ER- and PgR- 21 (48)
Stage at initial diagnosis, n (%)  
 0 1 (2)
 I 3 (7)
 II 15 (34)
 III 14 (32)
 IV 11 (25)
Number of prior metastatic chemotherapeutic regimen (s), n (%)  
 0 23 (52)
 1 21 (48)
Median time since first diagnosis, months (range) 28.8 (1–126)
Prior anti-cancer therapy, n (%) 43 (98)
 Chemotherapy 35 (80)
 Immunotherapy 1 (2)
 Hormonal therapy 18 (41)
 Biologic therapy 35 (80)
 Surgery 43 (98)
 Radiotherapy 23 (52)
  1. *All patients were female. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, Human epidermal growth factor receptor 2; IHC, immunochemistry; PgR, progesterone receptor.